1/20
03:10 pm
mdxg
MiMedx Group (NASDAQ:MDXG) had its price target lowered by analysts at Lake Street Capital from $12.00 to $10.00. They now have a "buy" rating on the stock.
Low
Report
MiMedx Group (NASDAQ:MDXG) had its price target lowered by analysts at Lake Street Capital from $12.00 to $10.00. They now have a "buy" rating on the stock.
1/16
08:51 am
mdxg
Recent 8.9% pullback isn't enough to hurt long-term MiMedx Group (NASDAQ:MDXG) shareholders, they're still up 70% over 3 years [Yahoo! Finance]
Low
Report
Recent 8.9% pullback isn't enough to hurt long-term MiMedx Group (NASDAQ:MDXG) shareholders, they're still up 70% over 3 years [Yahoo! Finance]
12/22
10:36 am
mdxg
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel [Yahoo! Finance]
Low
Report
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel [Yahoo! Finance]
12/22
09:43 am
mdxg
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel
Low
Report
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel
12/20
08:22 am
mdxg
With 47% stake, MiMedx Group, Inc. (NASDAQ:MDXG) seems to have captured institutional investors' interest [Yahoo! Finance]
Low
Report
With 47% stake, MiMedx Group, Inc. (NASDAQ:MDXG) seems to have captured institutional investors' interest [Yahoo! Finance]
12/19
10:09 am
mdxg
MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro [Yahoo! Finance]
Low
Report
MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro [Yahoo! Finance]
12/19
09:00 am
mdxg
MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro
Low
Report
MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro
12/17
08:24 am
mdxg
MiMedx Group (NASDAQ:MDXG) had its price target lowered by analysts at Mizuho from $12.00 to $10.00. They now have an "outperform" rating on the stock.
Low
Report
MiMedx Group (NASDAQ:MDXG) had its price target lowered by analysts at Mizuho from $12.00 to $10.00. They now have an "outperform" rating on the stock.
12/17
03:51 am
mdxg
?????????? - ??????????????????2026-2035? [CNET News]
Low
Report
?????????? - ??????????????????2026-2035? [CNET News]
11/17
01:42 pm
mdxg
MiMedx (MDXG) Just Flashed Golden Cross Signal: Do You Buy? [Yahoo! Finance]
Low
Report
MiMedx (MDXG) Just Flashed Golden Cross Signal: Do You Buy? [Yahoo! Finance]
11/14
01:16 pm
mdxg
MiMedx Group (NASDAQ:MDXG) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
MiMedx Group (NASDAQ:MDXG) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
08:38 am
mdxg
MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial [Yahoo! Finance]
Low
Report
MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial [Yahoo! Finance]
11/13
08:00 am
mdxg
MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial
Low
Report
MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial
11/10
04:01 pm
mdxg
MIMEDX to Participate in Upcoming Investor Conferences
Low
Report
MIMEDX to Participate in Upcoming Investor Conferences
11/3
09:15 am
mdxg
MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule
Low
Report
MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule
11/2
01:15 am
mdxg
11/2
01:15 am
mdxg
10/30
10:01 pm
mdxg
MiMedx Group (MDXG): Margin Decline Challenges Bullish Narratives Despite Strong Earnings Growth [Yahoo! Finance]
Low
Report
MiMedx Group (MDXG): Margin Decline Challenges Bullish Narratives Despite Strong Earnings Growth [Yahoo! Finance]
10/29
04:01 pm
mdxg
MIMEDX Announces Record Revenue for Third Quarter 2025
Low
Report
MIMEDX Announces Record Revenue for Third Quarter 2025
10/25
12:09 pm
mdxg
MiMedx Group (NASDAQ:MDXG) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
MiMedx Group (NASDAQ:MDXG) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.